FEDERALlobbying filing

Acadia Pharmaceuticals Lobbying Report: Q2 2026

Original title: ACADIA PHARMACEUTICALS → ACADIA PHARMACEUTICALS (2nd Quarter Report 2026)

July 20, 2026

Lobbying Healthcare Medicare Pharmaceuticals Taxation Trade

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This report discloses the specific legislative priorities and financial resources Acadia Pharmaceuticals is directing toward federal agencies and Congress to influence healthcare and tax policy.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Medicare and Medicaid enrollees

The company is lobbying on policies that impact access to medicines and antipsychotic use within these programs.

Parkinson's disease patients

The company is lobbying on issues related to access to medicines specifically for this patient population.

Acadia Pharmaceuticals

The company is actively seeking to influence federal legislation and agency policy regarding drug pricing and healthcare access.

What changed

Last recorded activity July 20, 2026.

What's next

Next step not available in the current record.

Summary

Acadia Pharmaceuticals reported $700,000 in lobbying expenditures for the second quarter of 2026. The company focused its advocacy efforts on federal healthcare legislation, Medicare and Medicaid policy, tax codes, and trade issues.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

How much did Acadia Pharmaceuticals spend on lobbying in Q2 2026?

The company reported $700,000 in lobbying expenses for this period.

What are the primary healthcare issues Acadia Pharmaceuticals is lobbying on?

The company is focused on Medicare and Medicaid access, Parkinson's disease treatments, antipsychotic medication use, and the implementation of the Inflation Reduction Act.

Which federal agencies were targeted by these lobbying efforts?

The company lobbied the U.S. Senate, the U.S. House of Representatives, the Food & Drug Administration (FDA), and the Department of the Treasury.

Why It Matters

This report discloses the specific legislative priorities and financial resources Acadia Pharmaceuticals is directing toward federal agencies and Congress to influence healthcare and tax policy.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Lobbying Activity

ACADIA PHARMACEUTICALS

$700,000

2026

HEALTH ISSUESMEDICARE/MEDICAIDTAXATION/INTERNAL REVENUE CODETRADE (DOMESTIC/FOREIGN)

“Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.”

View filing →

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Broad Legislative Focus

The registrant is simultaneously lobbying on a wide array of specific disease-related bills (Parkinson's, Alzheimer's, Kids' access) alongside major structural legislation like the Inflation Reduction Act.

Acadia Pharmaceuticals

Connected Entities

personSarah Tellock“Registered lobbyist for Acadia Pharmaceuticals.”Map →

organizationFood & Drug Administration“Target of lobbying efforts.”Map →

organizationU.S. Senate“Target of lobbying efforts.”Map →

organizationTreasury - Dept of“Target of lobbying efforts.”Map →

organizationU.S. House of Representatives“Target of lobbying efforts.”Map →

organizationAcadia Pharmaceuticals“The company filing the lobbying report.”Map →

personMichael Mattoon“Registered lobbyist for Acadia Pharmaceuticals.”Map →

Sources

Open source document

disclosurespreview.house.gov

Analysis Score

0–100

Significance65
How much this matters to a regular citizen
Controversy40
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz20
Current news / social attention level

Publisher tools